Clinical Trial Update: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating Evexomostat plus a PI3K or AKT inhibitor and fulvestrant in patients with PI3K alterations and HR+/HER2-negative breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Evexomostat
• Fulvestrant (fulvestrant)

Snippet

Sponsor: SynDevRx, Inc. | Conditions: HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING